Molecular biology of cervical cancer

Clinical and Translational Oncology

Volumn 9, Issue 6, 2007, Pages 347-354

  Gonzalez Martin A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Carcinogenesis; Cervical cancer; Human papilloma virus; New targets

Indexed keywords

BORTEZOMIB; CISPLATIN; EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEFITINIB; PROTEASOME; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN RECEPTOR; WART VIRUS VACCINE; PAPILLOMA VIRUS VACCINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PREVENTION; CANCER RISK; CELL PROLIFERATION; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA DAMAGE; DRUG SYNTHESIS; EPIGENETICS; GENETIC SCREENING; HUMAN; MOLECULAR BIOLOGY; MULTIPARA; NONHUMAN; ORAL CONTRACEPTION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VIRUS ASSEMBLY; VIRUS CARCINOGENESIS; VIRUS INFECTIVITY; VIRUS MORPHOLOGY; VIRUS REPLICATION; WART VIRUS; WOMEN'S HEALTH; ALPHAPAPILLOMAVIRUS; FEMALE; PHYSIOLOGY; REVIEW; UTERINE CERVIX TUMOR; VIROLOGY;

ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; MOLECULAR BIOLOGY; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 34848922746     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0066-8     Document Type: Article

References (57)

1. WHO (2006) World Health Organization Report: Comprehensive cervical cancer control: A guide to essential practice. Available on WWW at www.who.int/reproductive-health/publications/cervical_cancer_gep/ index.htm
2. Parkin M, Bray F (2006) The burden of HPV-related cancers. Vaccine 24[Suppl 3]:S11-S25
3. Clifford GM, Smith JS, Plummer M et al (2003) Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 88:63-73
4. Persson G, Andersson K, Krantz I (1996) Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture. Acta Obstet Gynecol Scand 75:287-290
5. Woodman CB, Collins S, Winter H et al (2001) Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 357:1831-1836
6. Richardson H, Kelsall G, Tellier P et al (2003) The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12:485-490
7. Clifford GM, Rana RK, Franceschi S et al (2005) Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14:1157-1164
8. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
9. zur Hausen H (2002) Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2:342-350
10. Baker CC, Phelps WC, Lindgren V et al (1987) Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 61:962-967
11. Shafti-Keramat S, Handisurya A, Kriehuber E et al (2003) Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77:13125-13135
12. Summerford C, Bartlett JS, Samulski RJ (1999) ?-5-integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med 5:78-82
13. Culp TD, Christensen ND (2004) Kinetics of in vitro adsorption and entry of papillomavirus virions. Virology 319:152-161
14. Bousarghin L, Touze A, Sizaret PY, Coursaget P (2003) Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J Virol 77:3846-3850
15. You J, Croyle JL, Nishimura A et al (2004) Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 117:349-360
16. Brehm A, Nielsen SJ, Miska EA et al (1999) The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 18:2449-2458
17. Antinore MJ, Birrer MJ, Patel D et al (1996) The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J 15:1950-1960
18. Funk JO, Waga S, Harry JB et al (1997) Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV16 E7 oncoprotein. Genes Dev 11:2090-2100
19. Thomas M, Pim D, Banks L (1999) The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18:7690-7700
20. Thomas M, Banks L (1998) Inhibition of Bakinduced apoptosis by HPV-18 E6. Oncogene 17:2943-2954
21. Li B, Dou QP (2000) Bax degradation by the ubiquitin/ proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci USA 97:3850-3855
22. Munger K, Baldwin A, Edwards KM et al (2004) Mechanism of human papillomavirus-induced oncogenesis. J Virol 78:11451-11460
23. Middleton K, Peh W, Southern SA et al (2003) Organisation of the human papillomavirus productive cycle during neoplastic progression provides a basis for the selection of diagnostic markers. J Virol 77:10186-10201
24. Florin L, Sapp C, Streeck RE, Sapp M (2002) Assembly and translocation of papillomavirus capsid proteins. J Virol 76:10009-10014
25. Day PM, Roden RBS, Lowy DR, Schiller JT (1998) The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1 and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol 72:142-150
26. Moscicki AB, Schiffman M, Kjaer S, Villa L (2006) Updating the natural history of HPV anogenital cancer. Vaccine 24[Suppl 3]:S42-51
27. Fujii T, Masumoto N, Saito M et al (2005) Comparison between in situ hybridization and real-time PCR technique as a means of detecting the integrated form of human papillomavirus 16 in cervical neoplasia. Diagn Mol Pathol 14:103-108
28. Yu T, Ferber MJ, Cheung TH et al (2005) The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet 158: 27-34
29. Frattini MG, Hurst SD, Lim HB et al (1997) Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumour suppressor protein. EMBO J 16:318-331
30. Duensing S, Munger K (2002) The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 62:7075-7082
31. Duensing S, Duensing A, Flores ER et al (2001) Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J Virol 75:7712-7716
32. Schaeffer AJ, Nguyen M, Liem A et al (2004) E6 and E7 oncoproteins induce distinct patterns of chromosomal aneuploidy in skin tumors from transgenic mice. Cancer Res 64:538-546
33. Duensing S, Munger K (2004) Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. Int J Cancer 109:157-162
34. Helt AM, Galloway DA (2003) Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24:159-169
35. Klingelhutz AJ, Foster SA, McDougall JK (1996) Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380:79-82
36. Hellberg D, Stendahl U (2005) The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer. Anticancer Res 25:3041-3046
37. Haverkos HW (2003) Viruses, chemicals and cocarcinogenesis. Oncogene 23:6492-6499
38. Moodley J (2004) Combined oral contraceptives and cervical cancer. Curr Opin Obstet Gynecol 16:27-29
39. Muñoz N, Catellsague X, Berrington A, Gissmann L (2006) HPV in the etiology of human cancer. Vaccine 24[Suppl 3]:S1-S10
40. Dueñas-González A, Lizano M, Candelaria M et al (2005) Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 4:38
41. Zambrano P, Segura-Pacheco B, Pérez-Cárdenas E et al (2005) A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 5:44
42. Stanley M, Lowy DR, Frazer I (2006) Prophylactic HPV vaccines: underlying mechanisms. Vaccine 24[Suppl 3]:S106-S113
43. Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4, 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367:1247-1255
44. Villa LL, Costa RL, Petta CA et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young woman: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278
45. Giroglou T, Sapp M, Lane C et al (2001) Immunological analyses of human papillomavirus capsids. Vaccine 19:1783-1793
46. Fleury MJ, Touze A, Alvarez E et al (2006) Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol 151:1511-1523
47. Combita AL, Touze A, Bousarghin L et al (2002) Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76:6480-6486
48. Adams J (2004) The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360
49. Sunwoo JB, Chen Z, Dong G et al (2001) Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7:1419-1428
50. Russo SM, Tepper JE, Baldwin AS Jr et al (2001) Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kB. Int J Radiat Oncol Biol Phys 50:183-193
51. Mathur SP, Mathur RS, Young RC (2000) Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer. Am J Reprod Immunol 44:222-230
52. Kersemaekers AM, Fleuren GJ, Kenter GG et al (1999) Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5:577-586
53. Vergote I, Humblet Y, van Cutsem E et al (2005) A multicenter Phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data. J Clin Oncol (2005) ASCO Annual Meeting Proceedings) 23[June 1 Supplement]:3162
54. Ferreira GG, Salgado M, Lima R et al (2006) A phase I trial of erlotinib (E), cisplatin (C) and radiotherapy (RT) for patients with locally advanced squamous cell cervical cancer. J Clin Oncol (2006 ASCO Annual Meeting Proceedings Part I) 24[June 20 Supplement]:13081
55. LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127-137
56. Steller MA, Delgado CH, Bartels CJ et al (1996) Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 56:1761-1765
57. Mathur SP, Mathur RS, Underwood PB et al (2004) Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Gynecol Oncol 91:486-493